Study of the SARS-CoV-2-specific immune T-cell responses in COVID-19-positive cancer patients.
Fiche publication
Date publication
mars 2021
Journal
European journal of cancer (Oxford, England : 1990)
Auteurs
Membres identifiés du Cancéropôle Est :
Pr ADOTEVI Olivier, Pr BORG Christophe, Pr WESTEEL Virginie, Mme BOUARD Adeline, Dr MANSI Laura, Dr VIENOT Angélique, Dr DAGUINDAU Etienne, Dr KROEMER Marie, Dr NARDIN Charlée
Tous les auteurs :
Mansi L, Spehner L, Daguindau E, Bouiller K, Almotlak H, Stein U, Bouard A, Kim S, Klajer E, Jary M, Meynard G, Vienot A, Nardin C, Bazan F, Lepiller Q, Westeel V, Adotévi O, Borg C, Kroemer M
Lien Pubmed
Résumé
Cancer patients are considered highly vulnerable to the COVID-19 pandemic. However, delaying cancer-specific therapies could have a deleterious effect on survival. The potential suppressive effects of chemotherapies or cancer-related microenvironment raised the question on how cancer patients' immune system responds to SARS-CoV-2 virus.
Mots clés
Cancer patients, Immune T cell response, SARS-CoV-2 antibodies, SARS-CoV-2 infection
Référence
Eur J Cancer. 2021 Mar 26;150:1-9